Post by Yelk on Apr 28, 2020 2:00:46 GMT
- VSTM is a turnaround story with new focus.
- P1 Data released this morning. Deemed good cancer data by everywhere I read
- Down nearly 50% on I believe a) a massive run up and b) resale SEC shelf of 46M shares today available
- This study will be followed by a Phase 2 study in 2020 which could be potentially registrational
- Just raised $100M with many institutions at these levels now.
- Currently $200M+ in cash so shouldn't need to raise until late 2021 with a $100M+ cash burn yearly.
- At an annual price of $300K/year, the estimated revenue opportunity in the U.S. is $40 billion/year. The company's current market cap is just $400 million, which is very low as compared to other KRAS-targeted companies like Mirati Therapeutics (MRTX) = $3.1 billion and Revolution Medicines (RVMD) = $1.1 billion.
- 30% of all human cancers are driven by KRAS mutations.
What is the opportunity?
There is too much to unpack with this stock in terms of revenue and pipeline but lots going on for such a small market cap. A lot of eyes on this stock. I am hoping a bit of a panic dip tested $2 o/u next day or two and then the bounce will start later. I see this is a very good spec play, but timing on when you buy is critical.
Will be watching this week for possible entries.